• IBA – Transparency Notification

    来源: Nasdaq GlobeNewswire / 19 2月 2021 13:35:00   America/New_York

     

    Louvain-la-Neuve, Belgium, February 19th, 2021, 07:30 pm

    Summary of the notification

    IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces the obligation to issue a publication, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 18th, 2021.

    In its notification, BlackRock, Inc. announces that, following a sale of voting shares, its shareholding in IBA SA has fallen below the 1% threshold for shares with voting rights.

    Content of the notification

    ·Reason for the notification: Acquisition or disposal of voting securities or voting rights    
    ·Notification by : A parent undertaking or a controlling person
    ·Persons subject to the notification requirement:
    BlackRock Inc., 55 East 52nd Street, New York, NY, 10055, U.S.A.
    BlackRock (Netherlands) B.V, Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
    BlackRock Advisors (UK) Limited, 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
    BlackRock Asset Management Canada Limited, 161 Bay Street,, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
    BlackRock Fund Advisors, 400 Howard Street, San Francisco, CA, 94105, U.S.A.
    BlackRock Institutional Trust Company, National Association, 400 Howard Street, San Francisco, CA, 94105, U.S.A.
    BlackRock Investment Management, LLC, 1 University Square Drive, Princeton, NJ, 8540,, U.S.A.

    • Date on which the threshold is crossed: 17/02/2021
    • Threshold crossed (in %): 1%
    • Denominator: 38.254.747
    • Notified details:

              

    ·Full chain of controlled undertakings through which the holding is effectively held

    BlackRock, Inc.
    Trident Merger, LLC
    BlackRock Investment Management, LLC

    BlackRock, Inc.
    BlackRock Holdco 2, Inc.
    BlackRock Financial Management, Inc.
    BlackRock Holdco 4, LLC
    BlackRock Holdco 6, LLC
    BlackRock Delaware Holdings Inc.
    BlackRock Institutional Trust Company, National Association

    BlackRock, Inc.
    BlackRock Holdco 2, Inc.
    BlackRock Financial Management, Inc.
    BlackRock Holdco 4, LLC
    BlackRock Holdco 6, LLC
    BlackRock Delaware Holdings Inc.
    BlackRock Fund Advisors

    BlackRock, Inc.
    BlackRock Holdco 2, Inc.
    BlackRock Financial Management, Inc.
    BlackRock International Holdings, Inc. BR Jersey International Holdings L.P.
    BlackRock Holdco 3, LLC
    BlackRock Canada Holdings LP
    BlackRock Canada Holdings ULC
    BlackRock Asset Management Canada Limited

    BlackRock, Inc.
    BlackRock Holdco 2, Inc.
    BlackRock Financial Management, Inc.
    BlackRock International Holdings, Inc.
    BR Jersey International Holdings L.P.
    BlackRock Holdco 3, LLC
    BlackRock Cayman 1 LP
    BlackRock Cayman West Bay Finco Limited
    BlackRock Cayman West Bay IV Limited
    BlackRock Group Limited
    BlackRock Finance Europe Limited
    BlackRock Advisors (UK) Limited

    BlackRock, Inc.
    BlackRock Holdco 2, Inc.
    BlackRock Financial Management, Inc.
    BlackRock International Holdings, Inc.
    BR Jersey International Holdings L.P.
    BlackRock Holdco 3, LLC
    BlackRock Cayman 1 LP
    BlackRock Cayman West Bay Finco Limited
    BlackRock Cayman West Bay IV Limited
    BlackRock Group Limited
    BlackRock Finance Europe Limited
    BlackRock (Netherlands) B.V.

    ·Additional Information

    The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going below 1%.

    For further information, please contact:

    IBA

    Valérie Van Impe
    Paralegal
    +32 10 203 180

    legal@iba-group.com

    About IBA
    IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

    IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

     

    Attachment


分享